Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on Afatinib

Somatic epidermal growth factor receptor (EGFR) mutations are present in around 50% of Asian patients and in 10–15% of Caucasian patients with metastatic non-small cell lung cancer (NSCLC) of adenocarcinoma histology. The first-generation EGFR-tyrosine kinase inhibitors (TKIs) gefitinib and erlotini...

Descripción completa

Detalles Bibliográficos
Autores principales: Morin-Ben Abdallah, Sami, Hirsh, Vera
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5432609/
https://www.ncbi.nlm.nih.gov/pubmed/28560182
http://dx.doi.org/10.3389/fonc.2017.00097

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5432609/
https://www.ncbi.nlm.nih.gov/pubmed/28560182
http://dx.doi.org/10.3389/fonc.2017.00097

Ejemplares similares